FD-LSC-1人喉鱗癌細(xì)胞、返回列表頁

舉報(bào) 評價(jià)

參考價(jià)

面議

具體成交價(jià)以合同協(xié)議為準(zhǔn)

產(chǎn)品型號

品牌

廠商性質(zhì)生產(chǎn)商

所在地

在線詢價(jià) 加入對比查看聯(lián)系電話

更新時(shí)間：2025-02-12 12:47:03瀏覽次數(shù)：11次

聯(lián)系我時(shí)，請告知來自化工儀器網(wǎng)

同類優(yōu)質(zhì)產(chǎn)品更多>

Rat podocyte大鼠腎

參考價(jià) 面議
McA-RH7777大鼠肝癌細(xì)

參考價(jià) 面議
SDBMSCSD大鼠骨髓間充質(zhì)

參考價(jià) 面議
DSL-6A/C1 大鼠胰腺癌

參考價(jià) 面議
Walker256-TC大鼠乳

參考價(jià) 面議

產(chǎn)品分類品牌分類

細(xì)胞庫 / 細(xì)胞培養(yǎng): 細(xì)胞株 ATCC細(xì)胞原代細(xì)胞干細(xì)胞普通細(xì)胞

全部產(chǎn)品列表

產(chǎn)品簡介

FD-LSC-1人喉鱗癌細(xì)胞CatalogueNo

詳情介紹

FD-LSC-1 人喉鱗癌細(xì)胞
Catalogue No.: C1235
Product Format: a T25 flask
Culture Properties：貼壁
Complete Growth Medium: 89%H-DMEM+10%FBS+1%雙抗
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Application: Cells and cancer research
NOTE: FOR RESEARCH USE ONLY.

Components

Item	Specifications
a T25 flask	2X10⁶
Manual	1 copy

multimodal treatment.The primary goal of cancer immunotherapy is to elicit an immune response capable of eradicating established tumors and preventing tumor metastasis. One strategy to achieve this goal utilizes whole killed tumor cells as the primary immunogen. Killed tumor cells provide a comprehensive source of tumor-associated antigens (TAAs), thereby eliminating the need to identify individual antigens. Unfortunately,